Opioids are the most potent analgesics in clinical use; however, their powerful rewarding properties can lead to addiction. The scientific challenge is to retain analgesic potency while limiting the development of tolerance, dependence, and addiction. Both rewarding and analgesic actions of opioids depend upon actions at the mu opioid (MOP) receptor. Systemic opioid reward requires MOP receptor function in the midbrain ventral tegmental area (VTA) which contains dopaminergic neurons. VTA dopaminergic neurons are implicated in various aspects of reward including reward prediction error, working memory, and incentive salience. It is now clear that subsets of VTA neurons have different pharmacological properties and participate in separate circuits. The degree to which MOP receptor agonists act on different VTA circuits depends upon the behavioral state of the animal, which can be altered by manipulations such as food deprivation or prior exposure to MOP receptor agonists.
Opioids are the most potent analgesics in clinical use; however, their powerful rewarding properties can lead to addiction. The scientific challenge is to retain analgesic potency while limiting the development of tolerance, dependence, and addiction. Both rewarding and analgesic actions of opioids depend upon actions at the mu opioid (MOP) receptor. Systemic opioid reward requires MOP receptor function in the midbrain ventral tegmental area (VTA) which contains dopaminergic neurons. VTA dopaminergic neurons are implicated in various aspects of reward including reward prediction error, working memory, and incentive salience. It is now clear that subsets of VTA neurons have different pharmacological properties and participate in separate circuits. The degree to which MOP receptor agonists act on different VTA circuits depends upon the behavioral state of the animal, which can be altered by manipulations such as food deprivation or prior exposure to MOP receptor agonists.
Mu opioid receptors: function and dysfunction
Opioids are currently the most effective pain-relieving pharmaceuticals. However, they are also rewarding and their repeated use can lead to dependence and addiction. In fact, addiction to opioid analgesics is a growing socioeconomic and health problem with potentially serious consequences, documented by a rise in deaths due to overdose [1, 2] . A critical CNS locus for opioid reward is the VTA (see Glossary). Recent work indicates that there is great anatomical and pharmacological heterogeneity in VTA neurons and that there are numerous opioid synaptic actions within the VTA. Here, we review the role of VTA neurons in opioid reward and reinforcement, and the synaptic and neural circuit mechanisms by which opioids control VTA neuronal activity.
How are we using the term 'reward'? Although there is broad consensus that addicting drugs produce 'reward', inconsistency in the use of the term is an impediment to progress in understanding how these drugs influence behavior [3] . The word 'reward' can be used as a noun ('rats will work for a reward'), a verb ('he intends to reward the winner'), or an adjective (a rewarding flavor). Furthermore, even when used as a noun, it has several distinct meanings: it can refer to the rewarding agent itself (e.g., a food or drug reward) or to the subjective hedonic feeling (i.e., pleasure). In behavioral psychology, it typically is used to denote a CNS process that increases the future probability of a behavioral response that has produced a beneficial outcome; a more precise term for this process is 'positive reinforcement'. In this review, we focus on how the actions of mu opioid (MOP) receptor agonists in the VTA can produce positive reinforcement, a critical initial step leading to opioid addiction.
Positive reinforcement is not an elementary process; it comprises several inter-related processes occurring at different times (Figure 1 ) and each process is likely to require activation of a distinct and partially independent neural Feature Review Glossary Channelrhodopsin (ChR): a light-activated channel natively expressed in green algae that is now commonly artificially expressed in neurons to enable acute, time-locked experimenter control of neural activity. When open, the channels nonselectively pass cations, including H + , Na + , K + , and Ca 2+ .
Conditioned place preference (CPP): in this paradigm, a three-chamber apparatus is most commonly used, where each chamber has unique contextual cues. During training, drugs are administered and the animal is then confined for a period in one of the end chambers. In alternate training periods, vehicle is administered before placing the rat in a different chamber. Animals are later tested in a drug-free state by allowing them to roam freely with access to all chambers of the apparatus. If animals spend more time in the drug-associated chamber, we say that the drug produces a CPP. Drug self-administration: in this paradigm, animals are required to perform an operant action (typically a lever press or nose poke) to receive an infusion of drug. If rats emit more operant actions for the drug than for vehicle, it is evidence that the drug has a positively reinforcing action. Mu opioid peptide (MOP) receptor: a member of the opioid family of seven transmembrane domain G protein-coupled receptors (GPCRs) classified in part by their high amino acid sequence homology. Other members of the family include the delta, kappa, and orphanin receptors. MOP receptors are widely distributed throughout the peripheral and central nervous systems. MOP receptors can signal through a variety of downstream pathways but typically their actions are inhibitory [e.g., to inhibit glutamate or GABA release from terminals or to hyperpolarize neurons through a G-protein activated inwardly rectifying potassium channel (GIRK)] [70]. Reinforcement: a process that leads to an increase in the probability of an action that was previously followed by a beneficial outcome. Negative reinforcement refers specifically to removing an unpleasant stimulus or state (e.g., pain relief). Positive reinforcement occurs when the benefit does not require relief of an unpleasant state. Punishment refers to the process whereby a harmful outcome reduces the probability of the action preceding the outcome. Ventral tegmental area (VTA): a region in the midbrain that includes dopaminergic neurons of the A10 cell group [99] . It is immediately ventral to the red nucleus, caudal to the hypothalamus, and medial to and contiguous with the substantia nigra (SN) [100] . The VTA has been divided into five subdivisions (see Figure 3 in [101] ). There are three midline nuclei: the interfascicular, rostral linear, and caudal linear. The two lateral divisions are the parabrachial pigmented and paranigral nuclei, which extend laterally from these midline nuclei to the medial lemniscus and the medial edge of the SN. The original description of the VTA by Tsai did not include the midline nuclei (e.g., [101]); however, there is general agreement that the catecholaminergic A10 group as originally defined by Dahlstroem and Fuxe [99] includes dopamine neurons in all five of these subnuclei. At the time of writing, there was no evidence that the cytoarchitectonically described subdivisions of the VTA differ functionally. VTA neurons in each of the subnuclei project widely to several limbic areas implicated in motivation and positive reinforcement [21, 26, 102, 103 ] (see Figure 3 in [100] ) and the weight of current evidence supports the idea that the critical organizational principal for grouping VTA neurons is their projection target and neurotransmitter content rather than location within the VTA. 
